Evidence map›Paper›PMID 27177997›Full record

Trial reportJournal of neurology2016

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.

Sven Schippling, Paul O'Connor, Volker Knappertz, Christoph Pohl, Timon Bogumil, Gustavo Suarez, Stuart Cook, Massimo Filippi, Hans-Peter Hartung, Giancarlo Comi and 4 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Depression and anxiety in multiple sclerosis. Review of a fatal combination.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  6. Review
  7. Article
  8. Risk of depression in multiple sclerosis across disease-modifying therapies.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 5 countries.

Sven SchipplingDepartment of Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Medical Center Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland. sven.schippling@usz.ch.
Paul O'ConnorSt. Michael's Hospital, Toronto, Canada.
Volker KnappertzTeva Pharmaceuticals, Frazer, PA, USA.
Christoph PohlBayer HealthCare AG/Bayer Pharma AG, Berlin, Germany.
Timon BogumilBayer HealthCare AG/Bayer Pharma AG, Berlin, Germany.
Gustavo SuarezBayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Stuart CookRutgers-New Jersey Medical School, Newark, NJ, USA.
Massimo FilippiOspedale San Raffaele, Milan, Italy.
Hans-Peter HartungDepartment of Neurology, Medical Faculty, Heinrich-Heine-Universität, Düsseldorf, Germany.
Giancarlo ComiVita-Salute University, Milan, Italy.
Douglas R JefferyPiedmont Health Care, Mooresville, NC, USA.
Ludwig KapposNeurology, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Douglas S GoodinUniversity of California at San Francisco, San Francisco, CA, USA.
Barry ArnasonDepartment of Neurology, University of Chicago, Chicago, IL, USA.
Heinrich Heine University Düsseldorf · DEBayer (Germany) · DEBayer (United States) · USIRCCS Ospedale San Raffaele · ITPiedmont HealthCare · USRutgers, The State University of New Jersey · USSt. Michael's Hospital · CAUniversity Hospital Bonn · DEUniversity Hospital of Basel · CHUniversity of Chicago · USUniversity of Zurich · CHVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early experience in MS generated concerns that interferon beta treatment might provoke onset or worsening of depression. The objective of the study was to compare depression incidence in relapsing-remitting MS patients receiving interferon beta-1b (IFNB-1b) or glatiramer acetate (GA) in the BEYOND trial. 891/897 (99 %) of English, French, Spanish and Italian speakers among 2244 patients randomized (2:2:1) to receive either IFNB-1b 500 µg, 250 µg, or GA 20 mg QD for 2-3.5 years submitted Beck Depression Inventory Second Edition (BDI-II) scores at screening and serially thereafter, in which scores ≥14 indicated depression. Baseline BDI-II scores ≥14 were reported in 232/891 patients (26.3 %), with no meaningful difference among the three treatment arms noted at this or at any other time during the study including trial end. Percentages of patients depressed by BDI-II scores deviated little in any arm at any time (IFNB-1b 500 µg: 24.7 %, IFNB-1b 250 µg: 24.4 %, GA: 32.4 %). Antidepressant usage was likewise similar among the three treatment arms (IFNB-1b 500 µg: 33.7 %, IFNB-1b 250 µg: 31.8 %, GA: 28.8 %) as was depression severity and the frequency with which non-blinded treating physicians recorded depression as an adverse event (IFNB-1b 500 µg: 17.2 %, IFNB-1b 250 µg: 17.0 %, GA: 14.4 %). Treating physicians attributed depression to IFNB-1b 250 µg therapy in 53.6 % and to GA in 21.9 % of instances. This large, prospective, randomized-controlled MS dataset showed no increased risk of depression above baseline values with standard or double-dose IFNB-1b or GA QD treatment.

Indexed as

International CooperationAdjuvants, ImmunologicAdultAntidepressive AgentsDepressionDisease ProgressionDose-Response Relationship, DrugFemaleGlatiramer AcetateHumansIncidenceInterferon beta-1aMaleMiddle AgedMultiple SclerosisPsychiatric Status Rating ScalesAdjuvants, ImmunologicAntidepressive AgentsGlatiramer AcetateInterferon beta-1aBEYOND studyClinical trialDepressionGlatiramer acetateInterferon betaMultiple sclerosis

Identifiers

PMID27177997
PMCPMC4929160
OpenAlexW2352039407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.